-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] Since 2022, the executives of the pharmaceutical industry have changed frequently, and more than 150 executives of pharmaceutical companies have left, involving multinational pharmaceutical companies, local Biotech, traditional pharmaceutical companies, and Internet medical compani.
Among them, including the chairman of nearly 10 pharmaceutical companies, the reasons for resignation include job change, retirement, personal reasons,e.
Entering the second half of the year, the tide of resignation of pharmaceutical company executives is still freque.
According to incomplete statistics, more than 40 pharmaceutical company executives have resigned in Ju.
For example, on July 29, Zixin Pharmaceutical announced that .
Feng Youshun, the general manager of the company, applied for his resignation as the general manager of the company due to job transfer; on July 28, China Pharmaceutical issued an announcement saying that due to job adjustment, .
Wang Hongxin applied for his resignation The company's directors, members of the special committees of the board of directors and general managers will no longer hold any positions in the compa.
Now that the time has come to August, many pharmaceutical companies in the industry have announced the resignation of senior executives and core technicia.
On August 1, Kain Technology disclosed an announcement that Hou Jianhua, the company's core technical staff, resigned due to personal reasons and completed the resignation procedures recent.
It is reported that this is the second core technical staff of Kain Technology to leave this year after Xu Zhe.
As of now, the core technology team of Kain Technology has been reduced from 8 people in 2021 to 6 peop.
In fact, the frequent changes of executives in the pharmaceutical industry are closely related to the development of the indust.
In recent years, under the continuous promotion of the medical reform policy, the domestic pharmaceutical industry is undergoing earth-shaking chang.
For example, with the continuous deepening of centralized procurement and the continuous expansion of varieties, the profit of the generic drug business has shrunk, which is forcing pharmaceutical companies to accelerate their transformati.
In In this context, it has become the norm for companies to adjust their development strategies and make active personnel adjustmen.
Analysts believe that with the deepening of domestic pharmaceutical reforms, the changes in executives of domestic pharmaceutical companies will contin.
It is worth noting that under a series of favorable policies, China's innovative drug industry is developing rapidly, and while the market is prosperous, the demand for talents is increasing day by d.
In fact, from the current point of view, under the influence of factors such as larger space for display and richer remuneration packages, local innovative pharmaceutical companies have begun to attract more and more multinational pharmaceutical executives to jo.
On July 21, Janssen China announced the appointment of Wang Hong as the head of the Pulmonary Hypertension and Rheumatism Products Business Un.
Before joining Janssen, she was the Senior Marketing Manager of the Central Marketing Department of the Rare Disease Business Team of the Sanofi Pharmaceuticals Divisi.
On July 13, BeiGene announced the appointment of Chan Lee as general counsel, who worked for Sanofi before joining BeiGe.
It is expected in the industry that while executives in the pharmaceutical industry change frequently, it may become a trend that executives of multinational pharmaceutical companies leave and join local pharmaceutical compani.
Although the demand for talents continues to increase under the general trend of pharmaceutical innovation, at the same time, the requirements for talents are expected to continue to increa.
Analysts believe that in the future, the pharmaceutical industry's requirements for talents will mainly have three characteristics: first, the threshold for professional quality is relatively high; second, practitioners are required to have strong compliance capabiliti.
The third is to be able to adapt to changes in the mark.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Among them, including the chairman of nearly 10 pharmaceutical companies, the reasons for resignation include job change, retirement, personal reasons,e.
Entering the second half of the year, the tide of resignation of pharmaceutical company executives is still freque.
According to incomplete statistics, more than 40 pharmaceutical company executives have resigned in Ju.
For example, on July 29, Zixin Pharmaceutical announced that .
Feng Youshun, the general manager of the company, applied for his resignation as the general manager of the company due to job transfer; on July 28, China Pharmaceutical issued an announcement saying that due to job adjustment, .
Wang Hongxin applied for his resignation The company's directors, members of the special committees of the board of directors and general managers will no longer hold any positions in the compa.
Now that the time has come to August, many pharmaceutical companies in the industry have announced the resignation of senior executives and core technicia.
On August 1, Kain Technology disclosed an announcement that Hou Jianhua, the company's core technical staff, resigned due to personal reasons and completed the resignation procedures recent.
It is reported that this is the second core technical staff of Kain Technology to leave this year after Xu Zhe.
As of now, the core technology team of Kain Technology has been reduced from 8 people in 2021 to 6 peop.
In fact, the frequent changes of executives in the pharmaceutical industry are closely related to the development of the indust.
In recent years, under the continuous promotion of the medical reform policy, the domestic pharmaceutical industry is undergoing earth-shaking chang.
For example, with the continuous deepening of centralized procurement and the continuous expansion of varieties, the profit of the generic drug business has shrunk, which is forcing pharmaceutical companies to accelerate their transformati.
In In this context, it has become the norm for companies to adjust their development strategies and make active personnel adjustmen.
Analysts believe that with the deepening of domestic pharmaceutical reforms, the changes in executives of domestic pharmaceutical companies will contin.
It is worth noting that under a series of favorable policies, China's innovative drug industry is developing rapidly, and while the market is prosperous, the demand for talents is increasing day by d.
In fact, from the current point of view, under the influence of factors such as larger space for display and richer remuneration packages, local innovative pharmaceutical companies have begun to attract more and more multinational pharmaceutical executives to jo.
On July 21, Janssen China announced the appointment of Wang Hong as the head of the Pulmonary Hypertension and Rheumatism Products Business Un.
Before joining Janssen, she was the Senior Marketing Manager of the Central Marketing Department of the Rare Disease Business Team of the Sanofi Pharmaceuticals Divisi.
On July 13, BeiGene announced the appointment of Chan Lee as general counsel, who worked for Sanofi before joining BeiGe.
It is expected in the industry that while executives in the pharmaceutical industry change frequently, it may become a trend that executives of multinational pharmaceutical companies leave and join local pharmaceutical compani.
Although the demand for talents continues to increase under the general trend of pharmaceutical innovation, at the same time, the requirements for talents are expected to continue to increa.
Analysts believe that in the future, the pharmaceutical industry's requirements for talents will mainly have three characteristics: first, the threshold for professional quality is relatively high; second, practitioners are required to have strong compliance capabiliti.
The third is to be able to adapt to changes in the mark.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
